Mycosis fungoides and Sezary syndrome: clinical presentation, diagnosis, staging, and therapeutic management

被引:15
|
作者
Miyashiro, Denis [1 ]
Sanches, Jose Antonio [1 ]
机构
[1] Univ Sao Paulo, Hosp Clin, Med Sch, Div Clin Dermatol, Sao Paulo, Brazil
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
mycosis fundgoides; Sezary syndrome; cutaneous T cell lymphoma; histopathology; prognosis; treatment; T-CELL LYMPHOMA; PRIMARY CUTANEOUS LYMPHOMAS; LONG-TERM OUTCOMES; PROGNOSTIC-FACTORS; EUROPEAN-ORGANIZATION; FLOW-CYTOMETRY; UNITED-STATES; CLASSIFICATION-SYSTEM; INTERNATIONAL-SOCIETY; CLONAL HETEROGENEITY;
D O I
10.3389/fonc.2023.1141108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mycosis fungoides (MF) and Sezary syndrome (SS) are cutaneous T-cell lymphomas. MF is the most common cutaneous lymphoma, and it is classified into classic Alibert-Bazin MF, folliculotropic MF, pagetoid reticulosis, and granulomatous slack skin, each with characteristic clinical presentation, histopathological findings, and distinct clinical behaviors. SS is an aggressive leukemic variant of cutaneous lymphoma, and it is characterized by erythroderma, lymphadenopathy, and peripheral blood involvement by malignant cells. There is a wide range of dermatological manifestations of MF/SS, and prompt recognition is essential for early diagnosis. Skin biopsy for histopathology and immunohistochemical analysis is imperative to confirm the diagnosis of MF/SS. Histopathology may also provide information that may influence prognosis and treatment. Staging follows the TNMB system. Besides advanced stage, other factors associated with poorer prognosis are advanced age, male gender, folliculotropism in histopathology of patients with infiltrated plaques and tumors in the head and neck region, large cell transformation, and elevated lactate dehydrogenase. Treatment is divided into skin-directed therapies (topical treatments, phototherapy, radiotherapy), and systemic therapies (biological response modifiers, targeted therapies, chemotherapy). Allogeneic bone marrow transplantation and extracorporeal photopheresis are other treatment modalities used in selected cases. This review discusses the main clinical characteristics, the histopathological/immunohistochemical findings, the staging system, and the therapeutic management of MF/SS.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] New Options in Diagnosis and Management of Mycosis Fungoides and Sezary Syndrome
    Enke, Charles A.
    [J]. ONCOLOGY-NEW YORK, 2010, 24 (06): : 507 - 508
  • [2] Multidisciplinary Management of Mycosis Fungoides/Sezary Syndrome
    Berg, Sara
    Villasenor-Park, Jennifer
    Haun, Paul
    Kim, Ellen J.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (03) : 234 - 243
  • [3] Current therapeutic options in Mycosis fungoides and Sezary syndrome
    Albrecht, Jana Dorothea
    Nicolay, Jan Peter
    [J]. HAUTARZT, 2022, 73 (01): : 75 - 85
  • [4] Mycosis fungoides and Sezary syndrome
    Diamandidou, E
    Cohen, PR
    Kurzrock, R
    [J]. BLOOD, 1996, 88 (07) : 2385 - 2409
  • [5] Mycosis fungoides and Sezary syndrome
    Costello, Regis
    Farnault, Laure
    Bonnet, Nathalie
    Le Treut, Therese
    Poullin, Pascale
    Kahn-Perles, Brigitte
    [J]. HEMATOLOGIE, 2011, 17 (06): : 411 - 421
  • [6] Mycosis fungoides and the Sezary syndrome
    Foss, F
    [J]. CURRENT OPINION IN ONCOLOGY, 2004, 16 (05) : 421 - 428
  • [7] Mycosis fungoides and Sezary syndrome
    Hwang, Sam T.
    Janik, John E.
    Jaffe, Elaine S.
    Wilson, Wyndham H.
    [J]. LANCET, 2008, 371 (9616): : 945 - 957
  • [8] Mycosis fungoides and the Sezary syndrome
    Kim, YH
    Hoppe, RT
    [J]. SEMINARS IN ONCOLOGY, 1999, 26 (03) : 276 - 289
  • [9] Mycosis fungoides and Sezary syndrome
    Lee, Hyewon
    [J]. BLOOD RESEARCH, 2023, 58 : 66 - 82
  • [10] MYCOSIS FUNGOIDES - SEZARY SYNDROME
    ROENIGK, HH
    TAYLOR, JG
    [J]. ARCHIVES OF DERMATOLOGY, 1970, 101 (02) : 244 - &